WebDr. Borghaei’s special areas of interest include lung cancer, targeted therapy, monoclonal antibody therapy, immunotherapy, and cancer vaccines. With regard to lung cancer, he is especially passionate about prevention and early detection of the disease. Dr. Hossein Borghaei works to improve his patients’ immune response to cancer. WebJun 14, 2024 · July 26th 2024. Hossein Borghaei, DO, MS, chief of the Division of Thoracic Medical Oncology, professor of the Department of Hematology/Oncology, and co-director of the Immune Monitoring Facility ...
Hossein Borghaei, DO, MS, Discusses Future Research Directions in …
WebNov 12, 2024 · Hossein Borghaei, DO, MS. November 12, 2024 - AMG 757, a DLL3-directed, half-life extended bispecific T-cell engager (BiTE), was shown to have a feasible adverse effect (AE) profile in patients ... WebAug 30, 2024 · Hossein Borghaei, DO @HosseinBorghaei. Replying to @HosseinBorghaei @TumorBoardTues. and 24 others. 8/13 #TumorBoardTuesday #LungCancer ... tennis club aizenay
Nivolumab versus Docetaxel in Advanced Non-squamous Non …
WebJun 24, 2024 · Borghaei H, Pluzanski A, Caro RB, et al. Nivolumab (nivo) + ipilimumab (ipi) as first-line (1L) treatment for patients with advanced non-small cell lung cancer (NSCLC) with brain metastases ... WebApr 12, 2024 · Hossein Borghaei, DO, MS. Professor and Chief, Thoracic Medical Oncology The Gloria and Edmund M. Dunn Chair in Thoracic Oncology Department of Hematology and Oncology Fox Chase Cancer Center Philadelphia, Pennsylvania. Provided by. Provided by Clinical Care Options, LLC. Supporters. WebApr 11, 2024 · [5] Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med 2015; 373: 1627-39 [6] Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-smallcell lung cancer: two-year outcomes from two … triactin 8